Back to Alzheimers Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT02646982

NCT02646982
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

  • You have been told you have Mild Cognitive Impairment (MCI), meaning you have noticed memory problems yourself, and tests have confirmed your memory is below the expected level for your years of education
  • Your score on a standard memory test called the MoCA was below 26 (out of 30)
  • Your everyday functioning is mostly preserved, based on a standard questionnaire score below 9
  • Your rating on a standard scale used to measure thinking and memory problems is at a mild level (score of 0.5)
  • Brain scans or a spinal fluid test have shown the presence of a protein called amyloid in your brain (a feature linked to Alzheimer's disease)

Who may not be able to join:

  • You have had a bad reaction or cannot tolerate a group of blood pressure medicines called ARBs
  • You are currently taking ARBs or ACE inhibitors (two common types of blood pressure medicines)
  • You have been diagnosed with high blood pressure, or you are taking any medication specifically to treat high blood pressure
  • Your blood pressure is very low (top number below 110 or bottom number below 40)
  • You have kidney disease, high potassium levels, low platelet counts, or abnormal blood clotting levels (confirm with trial site)
  • You have an active serious physical or mental health condition that the study doctor feels could affect your safety or the study results
  • You have uncontrolled heart failure causing significant breathlessness or difficulty with physical activity
  • You have had a stroke in the past 3 years
  • You are unable to have an MRI scan (for example, due to metal implants or a pacemaker), AND you are also unable to have a spinal fluid test or an amyloid brain scan — note: if you cannot have an MRI but can complete all other parts of the study, you may still be considered
  • You have a history of raised pressure in the brain, or you have a tendency to bleed easily, or you take blood-thinning medicines such as warfarin, heparin, rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), or dabigatran (Pradaxa)
  • You are a woman who has not yet gone through menopause
  • You are not able to show that you understand and can agree to take part in the study yourself, and you do not have a trusted person (such as a family member) who can formally agree on your behalf
  • You are currently taking Lithium medication

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
Emory University
Registry
clinicaltrials_gov
Start date
30 June 2016
Est. completion
17 August 2020

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants With a Hypotensive Episode; Number of Participants With Symptoms of Hypotension; Number of Participants With Hypotensive Episodes and Symptoms; Number of Participants With Elevated Serum Creatinine; Number of Participants With Hyperkalemia; Number of Participants Discontinuing Study Medication

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov